EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Transine Therapeutics Poised for Growth with New CSO Hire and Tripling of Lab Space
Andy Billinton PhD appointed as Chief Scientific Officer Expansion into larger facilities at the Babraham Research Campus Cambridge, 23rd June 2022: Transine Therapeutics today announced
Kynos Builds Out Senior Management Team with Appointment of Dr Alison Strutt, a Seasoned Biotech and ex-GSK Executive, as CFO
Dr Alison Strutt joins Kynos senior management team as CFO Brings extensive strategic, transactional, and operational experience in biotech and large pharma to the Kynos
Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the
Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development
Company adds £4.6m additional seed funding Strengthens investor syndicate with Epidarex joining as a new investor Enhances ability to leverage unique SINEUP® platform and rapidly
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
Both monthly and every-other-month pegcetacoplan continued to reduce GA lesion growth compared to pooled sham at 18 months with all p-values (nominal) below 0.05 Treatment
Leucid Bio Chief Scientific Officer John Maher Publishes New Research on pCAR Technology
New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets
Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing
Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding